| (Values in U.S. Thousands) | Apr, 2024 | Apr, 2023 | Apr, 2022 | Apr, 2021 | Apr, 2020 |
| Sales | 32,364,000 | 31,227,000 | 31,686,000 | 30,117,000 | 28,913,000 |
| Sales Growth | +3.64% | -1.45% | +5.21% | +4.16% | -5.38% |
| Net Income | 3,677,000 | 3,758,000 | 5,040,000 | 3,606,000 | 4,789,000 |
| Net Income Growth | -2.16% | -25.44% | +39.77% | -24.70% | +3.41% |
Medtronic Inc (MDT)
91.10 x 20 91.65 x 35
Post-market by (Cboe BZX)
91.22 -0.65 (-0.71%) 03/20/25 [NYSE]
91.10 x 20 91.65 x 35
Post-market 91.22 unch (unch) 17:34 ET
for Thu, Mar 20th, 2025
Medtronic, Inc. acquired Ireland-based Covidien plc. The acquisition resulted in the formation of a new holding company incorporated in Ireland - Medtronic plc. The company currently generates revenues from four major segments - namely Cardiovascular Portfolio, Medical Surgical Portfolio, Neuroscience Portfolio and Diabetes. The Cardiovascular Portfolio, formerly reported as the Cardiac and Vascular Group, includes the Cardiac Rhythm & Heart Failure, Structural Heart & Aortic and Coronary & Peripheral Vascular divisions. The Medical Surgical Portfolio, formerly reported as the Minimally Invasive Therapies Group, includes the Surgical Innovations and the Respiratory, Gastrointestinal & Renal divisions. Neuroscience consists of Cranial & Spinal Technologies, Specialty The Neuroscience Portfolio, formerly reported as the Restorative Therapies Group, includes the Cranial & Spinal Technologies, Specialty Therapies, and Neuromodulation divisions.
Fiscal Year End Date: 04/30